Log in

ASX:EX1Exopharm Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/13/2020)
Today's Range
Now: A$0.21
50-Day Range
MA: A$0.21
52-Week Range
Now: A$0.21
Average VolumeN/A
Market Capitalization$20.05 million
P/E RatioN/A
Dividend YieldN/A
Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing clinical human therapeutics in Australia. It is developing Plexaris, an exosome derived from human platelets; and Exomeres, an exosome derived from adult stem cells. The company was founded in 2003 and is headquartered in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 9111 0026



Sales & Book Value

Annual Sales$38,871.00
Cash FlowA$0.06 per share
Book ValueA$0.07 per share



Market Cap$20.05 million
Next Earnings DateN/A
OptionableNot Optionable

Receive EX1 News and Ratings via Email

Sign-up to receive the latest news and ratings for EX1 and its competitors with MarketBeat's FREE daily newsletter.

Exopharm (ASX:EX1) Frequently Asked Questions

How has Exopharm's stock been impacted by COVID-19 (Coronavirus)?

Exopharm's stock was trading at A$0.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EX1 shares have decreased by 2.3% and is now trading at A$0.21. View which stocks have been most impacted by Coronavirus.

Has Exopharm been receiving favorable news coverage?

Headlines about EX1 stock have trended somewhat negative on Saturday, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Exopharm earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Exopharm.

Who are some of Exopharm's key competitors?

Who are Exopharm's key executives?

Exopharm's management team includes the following people:
  • Dr. Ian Dixon MBA, Ph.D., Company Founder, Technology Co-Founder, MD & Director
  • Dr. Gregor Lichtfuss, COO & Technology Co-Founder
  • Mr. David Rodney Parker B.Com, SAFin, ACIS, Non-Exec. Director & Company Sec. (Age 40)

What is Exopharm's stock symbol?

Exopharm trades on the ASX under the ticker symbol "EX1."

What is Exopharm's stock price today?

One share of EX1 stock can currently be purchased for approximately A$0.21.

How big of a company is Exopharm?

Exopharm has a market capitalization of $20.05 million and generates $38,871.00 in revenue each year.

What is Exopharm's official website?

The official website for Exopharm is www.exopharm.com.

How can I contact Exopharm?

The company can be reached via phone at 61 3 9111 0026.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.